BeiGene, Ltd. 13D and 13G filings for Leap Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-31 6:29 pm Unchanged |
2024-10-31 | 13D | Leap Therapeutics, Inc. LPTX |
BeiGene Ltd. BGNE |
1,215,306 3.170% |
0 (Unchanged) |
Filing |
| 2024-10-31 5:40 pm Purchase |
2024-10-31 | 13D | Leap Therapeutics, Inc. LPTX |
BeiGene Ltd. BGNE |
1,215,306 0.000% |
1,215,306 (New Position) |
Filing |